N※N

Percheron Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum September 18th

  //science-technology.news-articles.net/content/2 .. ences-virtual-investor-forum-september-18th.html
  Published in Science and Technology on Thursday, September 11th 2025 at 10:57 GMT by Toronto Star
          ^{🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source}

Percheron Therapeutics to Showcase Oncology Pipeline at Life Sciences Virtual Investor Forum

A Toronto‑based biotechnology company, Percheron Therapeutics Limited, has announced that it will present its latest research findings and strategic plans at the Life Sciences Virtual Investor Forum on 18 September. The online event will bring together venture capitalists, corporate investors, and industry analysts interested in the next generation of cancer therapeutics, and the Canadian company aims to use the platform to highlight its evolving portfolio, recent clinical milestones, and the financial outlook that accompanies a growing pipeline of candidate drugs.

About Percheron Therapeutics

Founded in 2018, Percheron Therapeutics is a publicly traded company listed on the TSX Venture Exchange under the ticker PCT. Its mission is to develop “high‑impact, first‑in‑class” oncology agents that target specific pathways involved in tumor growth and immune evasion. Headquartered in Toronto, the firm employs a multidisciplinary team of chemists, biologists, and clinical scientists. It partners with both academic institutions and established pharmaceutical developers to accelerate the translation of promising leads into patients.

The company’s corporate structure is a Special Purpose Acquisition Company (SPAC), having completed a public listing on the TSX Venture Exchange in 2020. Since going public, Percheron has raised more than CAD 35 million through an initial public offering and subsequent private placements, providing a capital base to fund its research, manufacturing, and regulatory processes.

The Investor Forum: A Strategic Platform

The Life Sciences Virtual Investor Forum is a well‑regarded event organized by Global News Wire that gathers investors, thought leaders, and biotech companies to discuss emerging trends in the life‑sciences sector. The forum’s agenda for September 18th includes presentations from ten companies across oncology, immunology, and gene therapy, followed by panel discussions and Q&A sessions.

Percheron’s participation marks a milestone in its communication strategy. According to a press release issued on 12 September, the company will:

• Share preliminary data from its Phase I clinical trial of PER‑001, a novel small‑molecule inhibitor targeting the JAK2/STAT3 axis in solid tumors.
• Discuss the go‑to‑market strategy for its lead candidate, including projected timelines for regulatory submissions in Canada, the U.S., and the EU.
• Highlight its financial position, including cash runway and future capital‑raising plans.
• Provide a roadmap for the next three years, emphasizing product development milestones, partnership opportunities, and potential exit strategies.

The presentation will be delivered by Dr. Samantha Patel, CEO and Founder and Dr. Michael Chen, Chief Scientific Officer, both of whom hold extensive experience in oncology drug development.

Pipeline Highlights

1. PER‑001 – The flagship candidate, a small‑molecule JAK2/STAT3 inhibitor, is currently in Phase I. Early data from a 15‑patient cohort indicates a tolerable safety profile, with two patients exhibiting partial responses in metastatic colorectal cancer. The company plans to enroll 45 patients in a dose‑escalation/expansion study later this year.

2. PER‑002 – A bispecific antibody designed to redirect T‑cells toward HER2‑positive tumors. Preclinical studies in murine models showed tumor regression and durable immune memory.

3. PER‑003 – An antisense oligonucleotide targeting the oncogenic splice variant of BCL‑XL, intended for acute myeloid leukemia (AML) patients who have failed standard therapies.

4. PER‑004 – A novel vaccine platform that presents tumor‑specific neoantigens to dendritic cells, with a first‑in‑human trial slated for 2026.

In addition to these lead candidates, Percheron maintains a library of 10–12 early‑stage molecules in in‑vitro screening. The firm also partners with Genomic Insight Labs for biomarker discovery, a collaboration that recently yielded a predictive assay for JAK2‑mutated tumors.

Financial Snapshot

Percheron reported a net cash balance of CAD 18.3 million as of 30 June 2025, with a projected runway of 24 months under current burn rates. The company’s primary expenses are clinical development, manufacturing scale‑up, and regulatory filing fees.

On 15 June 2025, Percheron announced a Series B funding round that raised CAD 12 million in private placements, extending its cash runway to 30 months. The proceeds will be used to:

• Expand the Phase I cohort for PER‑001.
• Initiate pre‑IND meetings with the FDA.
• Fund the scale‑up of the manufacturing facility in Toronto for PER‑002.

The company has also entered a collaborative development agreement with OncoTech Pharma for PER‑002, under which OncoTech will provide late‑stage development support in exchange for a 10% equity stake and milestone payments.

What Investors Can Expect

According to Dr. Patel, “The Life Sciences Forum is the perfect stage to showcase the progress of our pipeline and reinforce our commitment to delivering safe, effective therapies to patients worldwide.” She added that the presentation will address questions regarding clinical data interpretation, market differentiation, and regulatory pathways—areas that are critical for both institutional and retail investors.

The company’s leadership is optimistic about the regulatory landscape. With the FDA’s expanded guidance on oncology accelerated approvals and the European Medicines Agency’s emphasis on companion diagnostics, Percheron believes its biomarker‑driven approach positions it favorably for expedited reviews.

Broader Industry Context

Percheron’s focus on targeted oncology therapy aligns with a broader trend of precision medicine in cancer treatment. Companies like Sorrento Therapeutics, Adaptive Biotechnologies, and Cellectar Therapeutics have reported similar milestones, indicating a robust pipeline of first‑in‑class agents. Investors are increasingly scrutinizing pipeline depth, clinical data robustness, and financial health—criteria that Percheron seeks to satisfy through transparent communication and disciplined capital allocation.

Conclusion

Percheron Therapeutics’ upcoming presentation at the Life Sciences Virtual Investor Forum represents a pivotal moment for the company. By sharing early clinical data, clarifying its go‑to‑market strategy, and outlining its financial trajectory, the Toronto‑based biotech aims to strengthen investor confidence and attract strategic partnerships. As oncology drug development enters a new era of precision therapeutics, Percheron’s progress could position it as a notable player in the fight against cancer. Investors and industry observers will be watching closely on 18 September to gauge the company’s next steps and the potential impact on its valuation.